Cargando…

Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Detalles Bibliográficos
Autores principales:	Yan, Chen-Hua, Wang, Yu, Wang, Jing-Zhi, Chen, Yu-Hong, Chen, Yao, Wang, Feng-rong, Sun, Yu-Qian, Mo, Xiao-Dong, Han, Wei, Chen, Huan, Zhang, Xiao-hui, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402118/ https://www.ncbi.nlm.nih.gov/pubmed/30836977 http://dx.doi.org/10.1186/s13045-019-0715-8

Ejemplares similares

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant
por: Yan, Chen-Hua, et al.
Publicado: (2016)

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
por: Zhang, Cheng, et al.
Publicado: (2020)

Optimal FSH usage in revascularization of allotransplanted ovarian tissue in mice
por: Ma, Wen-Zhi, et al.
Publicado: (2017)

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis
por: Chang, Ying-Jun, et al.
Publicado: (2017)

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome
por: Kong, Jun, et al.
Publicado: (2022)

Prevalence and Distribution of Potential Vascularized Composite Allotransplant Donors, Implications for Optimizing the Donor-recipient Match
por: Mendenhall, Shaun D., et al.
Publicado: (2018)

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
por: Jullien, Maxime, et al.
Publicado: (2022)

SAT239 Deceased Donor Parathyroid Allotransplant For Sever Refractory Iatrogenic Hypoparathyroidism
por: Devon, Karen M, et al.
Publicado: (2023)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Fan, Shuang, et al.
Publicado: (2022)

Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Jing, et al.
Publicado: (2018)

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies
por: Gao, Xiao-Ning, et al.
Publicado: (2018)

Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants
por: Kong, Yuan, et al.
Publicado: (2016)

Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis
por: Lin, Li, et al.
Publicado: (2021)

Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia
por: Xiong, Wenjie, et al.
Publicado: (2023)

Medullary allotransplant in acute myeloblastic leukemia in a child
por: Buga Corbu, V, et al.
Publicado: (2014)

Vascularised composite allotransplants: Transplant of upper extremities and face
por: Iyer, Subramania
Publicado: (2015)

Effect of Immunosuppression on the Hybrid Skeleton of Vascularized Composite Allotransplants?
por: Kerr, Katelyn, et al.
Publicado: (2022)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

Adipose-derived stromal cells modulating composite allotransplant survival is correlated with B cell regulation in a rodent hind-limb allotransplantation model
por: Chen, Chien-Chang, et al.
Publicado: (2020)

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
por: Oliva, Stefania, et al.
Publicado: (2016)

Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL
por: Li, Si-Qi, et al.
Publicado: (2020)

Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
por: Liu, Diankun, et al.
Publicado: (2021)

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study
por: Chang, Ying-Jun, et al.
Publicado: (2020)

Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
por: Zhao, Peng, et al.
Publicado: (2021)

Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor
por: Sun, Yu-Qian, et al.
Publicado: (2021)

A Flow Dynamic Rationale for Accelerated Vascularized Composite Allotransplant Rejection
por: Robbins, Nicholas L., et al.
Publicado: (2019)

Abnormalities by Multicolor Flow Cytometry for Detection of Minimal Residual Disease in Recipients of Allo-HSCT Originating from Donors: A Cohort Study
por: Wang, Hui, et al.
Publicado: (2023)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

Allotransplanted Neurons Used to Repair Peripheral Nerve Injury Do Not Elicit Overt Immunogenicity
por: Liu, Weimin, et al.
Publicado: (2012)

Upregulation of Heme Oxygenase-1 Endues Immature Dendritic Cells With More Potent and Durable Immunoregulatory Properties and Promotes Engraftment in a Stringent Mouse Cardiac Allotransplant Model
por: Zhao, Yue, et al.
Publicado: (2018)

The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease
por: Zeng, Ya, et al.
Publicado: (2020)

Effect of Local Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor on Subcutaneously Allotransplanted Ovarian Tissue in Ovariectomized Mice
por: Gao, Jiangman, et al.
Publicado: (2015)

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
por: Murray, Nigel P, et al.
Publicado: (2019)

Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease
por: Mahmudi, Hossein, et al.
Publicado: (2022)

Engraftment of Allotransplanted Tumor Cells in Adult rag2 Mutant Xenopus tropicalis
por: Tulkens, Dieter, et al.
Publicado: (2022)

Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission
por: Hu, Guan-hua, et al.
Publicado: (2022)

Predicting Outcomes of Rat Vascularized Composite Allotransplants through Quantitative Measurement of Chimerism with PCR-Amplified Short Tandem Repeat
por: Cheng, Hui-Yun, et al.
Publicado: (2020)

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study
por: Zhang, Rui, et al.
Publicado: (2021)

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
por: Shapiro, Roman M., et al.
Publicado: (2022)

Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study
por: Xu, Lan-Ping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5duv49vljree6jnu6jsskgic8e